Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - YES by Chataway, J
“Inadequate outcome measures are the biggest impediment to successful clinical trials in 
progressive MS”. YES 
 
Jeremy Chataway  
Queen Square Multiple Sclerosis Centre, Department of Neuro-inflammation, UCL Institute of 
Neurology, University College London, London, UK 
jeremy.chataway@uclh.nhs.uk 
 
The closer progressive multiple sclerosis (MS) is approached, the more awkward it is to define and 
the more slippery it is to measure. Of course on one level it is easy – if 5 years previously a person 
affected by MS can walk or see or balance normally, but now they walk with a stick or have a visual 
acuity of 6/60 or are falling over, then it is clear (to anyone) that progression has occurred, 
whichever yardstick is used. No, the problem is that progression is (generally) slow, it is multi-
dimensional and the time frequency of such very hard clinical end-points is too low to be of value in 
the 2-3 year life span of trials in progressive MS. 
Returning to the title statement above, there are in particular two areas which must be thought 
about, since they are fundamental to the issues of outcome measures in progressive MS and a brief 
revision of these starts to clarify the issues at hand. 
The first is the science of clinical measurement. Turn to any medical statistics book1 and the key 
concepts include: biological variation, the skill of the observer, the interaction between the observer 
and the subject, and the precision with which the data are recorded. To take an everyday example: 
systolic blood pressure could be recorded to the nearest 10 mm Hg, or the nearest 5 mm Hg or the 
nearest 1 mm Hg. Some investigators would use Korotkov sound four, others five. Imprecision, or 
non-standardisation, has the capacity to greatly alter the final outcome. Continuing with blood 
pressure, it varies from day to day, and season to season. Replication and quantification of these 
rhythms is necessary standard statistical practice. 
In the measurement of progressive MS, by whatever means, the opportunities for error abound. 
Examples that easily come to mind would be the effect on fatigue on a walking distance; depression 
on a test of cognition; whether the functional electrical stimulator (FES) is consistently on or off 
when the 25 foot walk is recorded; the blinding of the subject, the assessor and all other trial 
personnel.    
The second is the properties of the outcome measures themselves, in particular the rating scales. 
The psychometric issues in neurology have been well reviewed in detail by experts in the field and 
only a few areas are used for illustration here, without going into the mathematical theories needed 
to enhance rating scale analysis, such as latent trait theories.2 In the Ashworth spasticity scale there 
are six categories ordered in increasing spasticity: from ‘no increase in muscle tone’ to ‘affected part 
rigid in flexion or extension’. They are ordinal (ranked) assignments and the absolute interval 
differences are unknown and are likely to have different meanings at different portions of the scale. 
Another major concern is that of construct validity, whether the scales actually measure the health 
concerns that they purport to measure. To spare the reader, I thought I’d leave out the Expanded 
Disability Status Scale (EDSS), which has been raked over many times before. Indeed the properties 
required were discussed in the MSJ 20 years ago and included: sensitivity, reliability, validity, 
independence of dimensions, ceiling effects.3 As we know, the EDSS comes up short. 
Yet the paradox is, that even when a concerted attempt is made to overcome these issues it may not 
succeed. The Multiple Sclerosis Functional Scale (MSFC), which is reliable, covers three major 
domains of interest, yields a single score which can be compared across studies, and has good 
correlations with indices such as MRI and quality of life. Despite all of these properties and their 
promise, when it comes down to it, as an outcome scale, in a trial, the MSFC was rejected by the 
regulators. Reasons given were that the summary Z score was seen as dimensionless and abstract.4 
Let down again by the outcome scale. 
Outcome problems are not confined to clinician or patient observed scales. As we were prompted 
recently in the MSJ, there are numerous traps for the unwary, with so called objective measures 
such as MRI in progressive MS.5 Brain atrophy is of course very current in phase 2 trials in 
progressive MS, but there are a number of issues which will add error to the result and therefore 
impede the outcome measurement. We are reminded of the effects of age, hydration status and 
drug-induced pseudoatrophy. Moreover as a worked example, the tool that is used, MRI, in the 
context of a scanner upgrade can change the atrophy rate by about 1.5%.5 Frightening, when 
considering a background rate of whole brain atrophy in progressive MS of about 0.5%/year. The 
confounding effects on more advanced MRI parameters, particularly in the heterogeneous multi-site 
environments of clinical trials will of course magnify the problem. 
Moreover the difficulties are not just confined to measuring human beings with progressive MS. In 
the parallel world of animal models, a similar suite of concerns and worries exist with outcomes and 
their measurement. In one survey of 2600 reports, which included Experimental Autoimmune 
Encephalomyelitis (EAE), a blinded assessment of outcome was reported in about 30% of studies, 
with the rate for EAE being only 20%.6 
I think it is clear from what has been said above, that from the basic to the complex outcome, from 
animal to human, in trying to solve a problem such as progressive MS, there is plenty that can and 
does go wrong. The numerous other hurdles, recruitment, drug choice and trial design, though 
problematic, are of a lower order of magnitude. 
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